The Th17/Treg imbalance exists in patients with heart failure with normal ejection fraction and heart failure with reduced ejection fraction

Clinica Chimica Acta

Volumn 411, Issue 23-24, 2010, Pages 1963-1968

  Li, Na ^a   Bian, Hongjun ^a   Zhang, Juan ^b   Li, Xiaoxing ^a   Ji, Xiaoping ^a   Zhang, Yun ^a  

^a SHANDONG UNIVERSITY   (China)

^b THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

Author keywords

Heart failure with normal ejection fraction; Heart failure with reduced ejection fraction; Regulatory T cells; T helper 17 cells

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ADULT; ARTICLE; CELL DENSITY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; TH17 CELL;

CASE-CONTROL STUDIES; CHRONIC DISEASE; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; STROKE VOLUME; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 77957754924     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.08.013     Document Type: Article

References (39)

1. Rauchhaus M., Doehner W., Francis D.P., et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000, 102:3060-3067.
2. Deswal A., Petersen N.J., Feldman A.M., et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001, 103:2055-2059.
3. Torre-Amione G. Immune activation in chronic heart failure. Am J Cardiol 2005, 95:3C-8C. discussion 38C-40C.
4. Yu Q., Watson R.R., Marchalonis J.J., Larson D.F. A role for T lymphocytes in mediating cardiac diastolic function. Am J Physiol Heart Circ Physiol 2005, 289:H643-H651.
5. Boissier M.C., Assier E., Falgarone G., Bessis N. Shifting the imbalance from Th1/Th2 to Th17/treg: the changing rheumatoid arthritis paradigm. Joint Bone Spine 2008, 75:373-375.
6. Yamaoka-Tojo M., Tojo T., Inomata T., et al. Circulating levels of interleukin 18 reflect etiologies of heart failure: Th1/Th2 cytokine imbalance exaggerates the pathophysiology of advanced heart failure. J Card Fail 2002, 8:21-27.
7. Cheng X., Ding Y., Xia C., et al. Atorvastatin modulates Th1/Th2 response in patients with chronic heart failure. J Card Fail 2009, 15:158-162.
8. Harrington L.E., Hatton R.D., Mangan P.R., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132.
9. Park H., Li Z., Yang X.O., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6:1133-1141.
10. Sakaguchi S. Naturally arising Foxp3-expressing CD25+ CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005, 6:345-352.
11. Homey B. After TH1/TH2 now comes Treg/TH17: significance of T helper cells in immune response organization. Hautarzt 2006, 57:730-732.
12. Bettelli E., Carrier Y., Gao W., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
13. Stewart S., MacIntyre K., Hole D.J., Capewell S., McMurray J.J. More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 2001, 3:315-322.
14. Jessup M., Brozena S. Heart failure. N Engl J Med 2003, 348:2007-2018.
15. Gage J.R., Fonarow G., Hamilton M., et al. Beta blocker and angiotensin-converting enzyme inhibitor therapy is associated with decreased Th1/Th2 cytokine ratios and inflammatory cytokine production in patients with chronic heart failure. Neuroimmunomodulation 2004, 11:173-180.
16. Mann D.L., Deswal A., Bozkurt B., Torre-Amione G. New therapeutics for chronic heart failure. Annu Rev Med 2002, 53:59-74.
17. Kirkham B.W., Lassere M.N., Edmonds J.P., et al. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum 2006, 54:1122-1131.
18. Krueger G.G., Langley R.G., Leonardi C., et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007, 356:580-592.
19. Duerr R.H., Taylor K.D., Brant S.R., et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006, 314:1461-1463.
20. Hashmi S., Zeng Q.T. Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron Artery Dis 2006, 17:699-706.
21. Eid R.E., Rao D.A., Zhou J., et al. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation 2009, 119:1424-1432.
22. Smith E., Prasad K.M., Butcher M., et al. Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation 2010, 121:1746-1755.
23. Rangachari M., Mauermann N., Marty R.R., et al. T-bet negatively regulates autoimmune myocarditis by suppressing local production of interleukin 17. J Exp Med 2006, 203:2009-2019.
24. Sonderegger I., Rohn T.A., Kurrer M.O., et al. Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur J Immunol 2006, 36:2849-2856.
25. Feng W., Li W. The study of ISO induced heart failure rat model. Exp Mol Pathol 2010, 88:299-304.
26. Yi A., Jian L., Xiaojing H., Hui X. The prevalence of Th17 cells in patients with dilated cardiomyopathy. Clin Invest Med 2009, 32:E144-E150.
27. Li J., Wang L., Wang S., et al. The Treg/Th17 imbalance in patients with idiopathic dilated cardiomyopathy. Scand J Immunol 2010, 71:298-303.
28. Nishikawa N., Yamamoto K., Sakata Y., et al. Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation. Cardiovasc Res 2003, 57:766-774.
29. Tang T.T., Ding Y.J., Liao Y.H., et al. Defective circulating CD4+ CD25+ Foxp3+ CD127(low) regulatory T-cells in patients with chronic heart failure. Cell Physiol Biochem 2010, 25:451-458.
30. Cheng X., Yu X., Ding Y.J., et al. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol 2008, 127:89-97.
31. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-1164.
32. Fontenot J.D., Rudensky A.Y. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol 2005, 6:331-337.
33. Solomou E.E., Rezvani K., Mielke S., et al. Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia. Blood 2007, 110:1603-1606.
34. Ait-Oufella H., Salomon B.L., Potteaux S., et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 2006, 12:178-180.
35. Kvakan H., Kleinewietfeld M., Qadri F., et al. Regulatory T cells ameliorate angiotensin II-induced cardiac damage. Circulation 2009, 119:2904-2912.
36. Platten M., Youssef S., Hur E.M., et al. Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Proc Natl Acad Sci USA 2009, 106:14948-14953.
37. Heymans S., Hirsch E., Anker S.D., et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2009, 11:119-129.
38. Owan T.E., Hodge D.O., Herges R.M., et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006, 355:251-259.
39. Bhatia R.S., Tu J.V., Lee D.S., et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006, 355:260-269.